(Reuters) -The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, ...

The FDA's top drug regulator, Dr. George Tidmarsh, quit after federal officials began reviewing "serious concerns about his ...

Dr. George Tidmarsh, the Food and Drug Administration’s top drug regulator, was placed on administrative leave and is ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

George Tidmarsh, who resigned Sunday, is accused in a lawsuit of seeking a bribe and defaming a drug.

George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory ...

More than 580,000 bottles of prazosin hydrochloride capsules have been recalled after tests found potential cancer-causing ...

Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug costs by removing extra clinical trial requirements.

The new operation would include U.S. troops on the ground in Mexico striking drug labs and cartel leaders, according to ...